Treatment of Sjögren's Syndrome with Mesenchymal Stem Cells: A Systematic Review.
Najwa ChihabyMarie OrliaguetLaëtitia Le PottierJacques-Olivier PersSylvie BoisraméPublished in: International journal of molecular sciences (2021)
Mesenchymal stem cells (MSCs) are ubiquitous in the human body. Mesenchymal stem cells were initially isolated from bone marrow and later from other organs such as fatty tissues, umbilical cords, and gingiva. Their secretory capacities give them interesting immunomodulatory properties in cell therapy. Some studies have explored the use of MSCs to treat Sjögren's syndrome (SS), a chronic inflammatory autoimmune disease that mainly affects exocrine glands, including salivary and lacrimal glands, although current treatments are only palliative. This systematic review summarizes the current data about the application of MSCs in SS. Reports show improvements in salivary secretions and a decrease in lymphocytic infiltration in salivary glands in patients and mice with SS after intravenous or infra-peritoneal injections of MSCs. MSC injections led to a decrease in inflammatory cytokines and an increase in anti-inflammatory cytokines. However, the intrinsic mechanism of action of these MSCs currently remains unknown.
Keyphrases
- mesenchymal stem cells
- cell therapy
- umbilical cord
- bone marrow
- systematic review
- end stage renal disease
- endothelial cells
- newly diagnosed
- ejection fraction
- chronic kidney disease
- case report
- gene expression
- disease activity
- palliative care
- multiple sclerosis
- meta analyses
- type diabetes
- emergency department
- big data
- electronic health record
- randomized controlled trial
- high fat diet induced
- metabolic syndrome
- rheumatoid arthritis
- high dose
- adverse drug
- patient reported outcomes
- data analysis
- adipose tissue
- advanced cancer